We are addressing unmet medical needs with a focus on RNA therapeutics, allergies, viral infections
Location: Bermuda, Hamilton
Employees: 11-50
Phone: +1 302-200-8095
Founded date: 2003
Mentions in press and media 18
| Date | Title | Description |
| 24.09.2024 | Biopharmaceuticals on the Rise: A Surge of Innovation and Investment | The biopharmaceutical sector is buzzing. Recent developments reveal a landscape rich with opportunity and innovation. Companies are securing funding, expanding their reach, and launching groundbreaking therapies. This surge is not just a ri... |
| 24.09.2024 | Financial boost for five publicly traded companies | Altamira Therapeutics, a biopharmaceutical company specializing in RNA-based therapeutics for extrahepatic targets, announced the closing of a public offering raising up to $12.0 million. The offering included Series A-1 and Series A-2 com... |
| 23.09.2024 | Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia | Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing authorization for Mainland China Extension of Exclusive License and Distribution Agreement to in... |
| 23.11.2023 | Altamira Therapeutics spins off part of its Bentrio business | |
| 26.05.2023 | Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis | Bentrio® meets primary efficacy endpoint in NASAR clinical trial in seasonal allergic rhinitis Clinically relevant and statistically significant improvement in Total Nasal Symptom Score over saline nasal spray control (p = 0.012) Bentrio ef... |
| 07.02.2023 | Altamira Therapeutics to Present at Two Upcoming RNA Therapeutics Conferences in Q1 2023 | New, trends and future of RNA-based therapeutics Company's OligoPhoreTM / SemaPhoreTM polyplexes provide for efficient delivery of siRNA payloads into extrahepatic target cells Company's latest research and insights into RNA-based therapies... |
| 12.07.2022 | Altamira Therapeutic’s RNA Delivery Platform Shown to be an Effective Treatment for Abdominal Aortic Aneurysm as Published in Peer-Reviewed Journal | Study results appeared in "Biomaterials Advances", a highly respected peer-reviewed journal, showcasing growing medical recognition of Company's patented RNA delivery platform for extrahepatic targets. Company's RNA delivery platf... |
| 29.06.2022 | Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan | Two Additional Distributors Further Expand Company's Growing Global Footprint To Offer Its Bentrio Nasal Spray for Protection Against Airborne Allergens and Viruses HAMILTON, BERMUDA / ACCESSWIRE / June 29, 2022 / Altamira Therapeutics Ltd.... |
| 27.06.2022 | Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis | Company gains access to the world's largest OTC market for consumer health products Expects substantial and growing US Bentrio revenue contribution over next couple of years HAMILTON, BERMUDA / ACCESSWIRE / June 27, 2022 / Altamira Therapeu... |
| 23.06.2022 | Altamira Therapeutics Achieves COVAMID Trial Target Enrollment for Bentrio in Acute COVID-19 | Reached targeted clinical trial enrollment of 136 subjects ahead of schedule At current patient enrollment, top-line data read-out is expected in Q3-22 HAMILTON, BERMUDA / ACCESSWIRE / June 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO... |
Show more